Abstract
The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders.
Cite
CITATION STYLE
APA
Drucker, D. J. (2025, February 1). Expanding applications of therapies based on GLP1: Incretin-based therapies in 2024. Nature Reviews Endocrinology. Nature Research. https://doi.org/10.1038/s41574-024-01066-9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free